Now showing items 1-2 of 2
Multifunctional enzyme inhibition for neuroprotection: a focus on MAO, NOS, and AChE inhibitors
Neurodegenerative disorders are known to be multifactorial in nature and current research focus has moved from a ‘one-drug-one-target approach’ to that of drugs which are able to act at various relevant biological targets. ...
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease
(Bentham Science, 2015)
The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ...